ArticleJournal of nanobiotechnology2026
Structural color-based microneedle patch with NIR-triggered on-demand drug release for intelligent treatment of infected wounds.
Article in Journal of nanobiotechnology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Hyaluronic Acid-Based Injectable Dual-Network Hydrogel for 6'-Sialyllactose Mimetic Peptide Delivery and Microenvironment Reconstruction in Brachial Plexus Root Avulsion.Advanced healthcare materials · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
Bacterial-infected wounds present a critical clinical challenge due to persistent inflammation, impaired angiogenesis, and the lack of real-time treatment monitoring. To address these issues, we developed an innovative colloidal crystal hydrogel microneedle (CT MNs) patch based on CuS nanoparticles (CuS NPs) and tannic acid-berberine nanoparticles (TB NPs). This system integrates synergistic antibacterial/antioxidant therapy with structural color-based drug release self-reporting capability. Specifically, the CT MNs combine photothermal CuS NPs for near‑infrared (NIR)-triggered hyperthermia and temperature‑controlled drug release, the release of TB NPs for potent antibacterial/antioxidant activities, and the color changes of the inverse opal colloidal crystal for real‑time monitoring of drug release. In vitro assays demonstrated strong antibacterial effects (95.65% and 95.92% against E. coli and S. aureus, respectively) and outstanding ROS‑scavenging capacity (92.93% for DPPH and 97.36% for ABTS⁺). In infected rat models, the CT MNs + NIR group achieved rapid wound closure (94.41% by day 10), significantly outperforming the controls. This accelerated healing was attributed to the synergistic effects of photothermal ablation, TB NPs-mediated bacterial clearance, and ROS-scavenging-driven inflammation alleviation. Therefore, this work presents a theranostic dressing that merges targeted combination therapy with non‑invasive optical monitoring of drug release, offering a promising strategy for intelligent wound management.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.